President Donald Trump announced on Monday new drug‑pricing agreements with nine pharmaceutical companies, aiming to supply state Medicaid programs at most‑favored‑nation (MFN) prices. The participating firms are Astellas (TYO:4503), BeOne Medicines (SHH:688235), CSL (ASX:CSL), BridgeBIO (NASDAQ:BBIO), Sun Pharmaceutical (NSE:SUN), Teva (TASE:TEVA) and UCB SA (EBR:UCB). Trump stated that the MFN model represents “a tremendous discount, which should bring down the cost of your medical care by tremendous amounts.”
The announcement expands on a prior set of agreements made last year with 17 major drugmakers, which included Pfizer (NYSE:PFE), Eli Lilly (NYSE:LLY) and Amgen (NASDAQ:AMGN). Those earlier deals required price reductions for federal health programs and allowed certain medicines to be sold directly to patients through a Trump‑branded website in exchange for tariff relief. The MFN pricing model obliges participating manufacturers to offer prices comparable to those paid in other developed nations, addressing the fact that Americans currently pay the highest prescription‑medicine prices among developed countries, often nearly three times those in peer economies.
No additional compliance timelines or conditions were detailed beyond the MFN pricing requirement. The article notes that the information was generated with AI assistance and reviewed by an editor.